|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
ABSTRACT |
|---|
|
|
|---|
Impaired adaptive immunity is the hallmark of AIDS, but the effects of human immunodeficiency virus type 1 (HIV-1) infection on
innate immunity are less clear. Cryptococcus neoformans (CN) is a
common AIDS-related fungal pathogen acquired by inhalation. Alveolar macrophages (AM
) comprise the initial host defense in cryptococcosis and they may arrest infection before dissemination occurs. We hypothesized that HIV-1 infection of AM
impairs their anti-cryptococcal activity. This was tested by infection of normal AM
with the M-tropic strain HIV-1Bal. Two weeks postinfection we measured fungistatic activity against CN by colony counting, binding, and internalization of CN by confocal microscopy and AM
cell viability by Alamar Blue assay. Uninfected AM
from
most donors demonstrated innate fungicidal activity against CN.
In HIV-1-infected AM
, there was a significant reduction, and in most cases loss, of fungicidal activity compared with the uninfected AM
. The reduced antifungal activity was not due to any
cytotoxic effect of HIV-1, and HIV-1 infection did not impair binding or internalization of yeast by AM
. Thus, the innate fungicidal
activity of primary human AM
is impaired after HIV-1 infection in
vitro by a mechanism involving a defect of intracellular antimicrobial processing.
| |
INTRODUCTION |
|---|
|
|
|---|
In the lung, the alveolar macrophage (AM
) is a key mediator
of innate immunity and plays a central role in cell-mediated adaptive immunity. In contrast to the well studied deleterious effects on T cell numbers and function, the impact of acquired immunodeficiency syndrome (AIDS) on innate immunity mediated by monocytes/macrophages is unclear. A variety of
monocyte/macrophage functional perturbations in human immunodeficiency virus type 1 (HIV-1)-infected persons have
been reported, including augmented cytokine release (e.g., interleukin 1 [IL-1], IL-6, and tumor necrosis factor [TNF]) (1,
2) and impaired phagocytosis of certain AIDS copathogens including Pneumocystis carinii (3). Analysis of AM
function in
the setting of AIDS is complicated by a plethora of uncontrolled clinical variables in addition to the well-recognized donor variability of many AM
responses measured in vitro or in
vivo. For that reason, in vitro HIV-1 infection of AM
from
healthy donors has been employed to investigate mechanisms of viral pathogenesis. Given the relatively low level of HIV-1 infection and expression in AM
from HIV-1-infected persons without clinical lung disease (4), the physiological relevance of in vitro studies has been questioned. However, studies by Koziel and coworkers (5), and others (6), suggest that
pulmonary viral load and the proportion of AM
infected
with HIV-1 may be greatly increased during coinfection with a
variety of bacterial and fungal pathogens.
Cryptococcus neoformans (CN) is one of the most common
causes of fatal fungal infection in AIDS (9). Cryptococcosis is acquired by inhalation, and AM
are the initial effector cells of host defense. The yeast bind to several different receptor types on AM
, and phagocytosis may be followed by growth
suppression and killing of internalized yeast even in the absence of T lymphocytes (10, 11). Cryptococcosis is therefore
a relevant infection for the investigation of HIV-1-mediated
macrophage dysfunction, and one that may reflect AM
mechanisms directed at a variety of other pathogens. We investigated the antifungal performance of AM
infected with
HIV-1Bal challenged with CN, and found evidence of a virus-mediated impairment of antimicrobial activity.
| |
METHODS |
|---|
|
|
|---|
Reagents
Culture medium consisted of RPMI 1640 with penicillin (50 U/ml),
streptomycin (50 µg/ml) (BioWhittaker, Walkersville, MD), and 10%
fetal bovine serum (FBS; GIBCO, Grand Island, NY). Pooled human
serum (PHS) was obtained by combining under ice-cold conditions serum from 10 healthy donors, and storing it at
70° C to preserve complement activity.
Bronchoalveolar Lavage Cells
Bronchoalveolar lavage (BAL) of nonsmoking healthy volunteers
was performed by a standard protocol (12) approved by Institutional Review Board of Boston Medical Center. After informed written consent was obtained, 240 ml of sterile saline was instilled in 60-ml aliquots through a bronchoscope and recovered by gentle aspiration.
BAL fluid was strained through a single layer of gauze, then centrifuged for 12 min at 300 × g. BAL cells (BALCs) were washed once in
RPMI 1640. Differential counts were made on Diff-Quik- and nonspecific esterase (Sigma, St. Louis, MO)-stained cell preparations. AM
were isolated by adherence. BALCs (5 × 105) were plated in
24-well cell culture plates (Corning, Corning, NY) in a final volume
of 2 ml and incubated for 24 h at 37° C in humidified air supplemented
with 5% CO2. Nonadherent cells were then removed by vigorous washing and the remaining adherent cells were, on average, > 98% viable
(trypan blue dye exclusion), > 95% esterase positive, and > 95%
phagocytic (latex beads).
HIV-1 Infections
M-tropic HIV-1Bal was obtained from G. Viglianti (Boston University
School of Medicine, Boston, MA) as cell-free supernatant of infected
human peripheral blood mononuclear cell cultures. AM
were inoculated with 3 ng of p24 antigen/105 cells. Control AM
received only
medium. Cells were placed on a rocker and incubated for 4 h at 37° C
in humidified air supplemented with 5% CO2. The cells were then
washed and cultured in fresh medium. Unless otherwise specified, all
in vitro infections were conducted for 2 wk. Every 3 d, media were aspirated, filtered, and stored at
70° C for later analysis.
HIV-1 p24 Antigen Detection
Two techniques were employed to measure p24 antigen. To confirm
HIV-1 infection of AM
, measurement of p24 antigen in culture supernatant was performed by enzyme-linked immunosorbent assay (ELISA)
(Beckman-Coulter, Brea, CA) according to the manufacturer instructions. Results are expressed as picograms of antigen per milliliter of supernatant. To determine the fraction of HIV-1-infected AM
in culture,
intracellular p24 was measured by flow cytometry. After aspirating the
supernatant, HIV-1-infected AM
and uninfected controls were detached from culture wells by vigorous pipetting with 1 ml of phosphate-buffered saline (PBS) with 1% bovine serum albumin (BSA) and scraping with the pipette tip. The cells were pelleted, resuspended in 100 µl of
Fixation Medium A (Caltag, Burlingame, CA), incubated at room temperature for 15 min, and washed. Cells were permeabilized in 100 µl of
Permeabilization Medium B (Caltag), blocked with murine IgG1 (Beckman-Coulter) for 15 min, and stained with KC57-phycoerythrin (PE)
antibody (20 µg/ml, Beckman-Coulter), which recognizes HIV-1 core
antigens, or with PE-conjugated isotype control antibody (20 µg/ml;
Beckman-Coulter) for 15 min (13). The monoclonal KC57-PE antibody
is specific for the intracytoplasmic staining of HIV-infected cells as confirmed by correlate reverse transcriptase activity (14). Cells were washed,
resuspended, and fixed in 1% formalin (Fisher Scientific, Fair Lawn, NJ).
Stained AM
were analyzed on a Becton Dickinson (Mountain View,
CA) FACScan. Live gating on AM
by forward-versus-side scatter characteristics was used to collect 10,000 events. Collected data were analyzed
by CellQuest software (Becton Dickinson), generating histograms for the
FL-2 channel. Isotype controls for each specimen were used to determine
the 95% confidence interval of nonspecific fluorescence.
Cryptococcus neoformans
Serotype A strain 145 was maintained by serial passages on Sabouraud dextrose plates (Remel, Lenexa, KS) at 30° C. For the antifungal assay, a single colony was harvested from Day 5 cultures and resuspended in 1.0 ml of RPMI 1640. A yeast suspension was obtained by vortexing for 30 s and repeated aspirations through a 25-gauge needle. The fungi were then counted on a hemacytometer and diluted to a final concentration of 1.6 × 104 fungal cells per milliliter of RPMI 1640 with 10% PHS.
Antifungal Assay
Antifungal activities were measured on selected days in cultures of uninfected and HIV-1-infected AM
as previously described (15, 16). Briefly,
culture medium was replaced with RPMI 1640 plus 10% PHS. AM
were
infected with CN 145 (1:50 yeast:macrophage) and incubated at 37° C in
humidified air supplemented with 5% CO2. After 18 h cell cultures were
lysed with 0.1% Triton X-100 (Fisher Scientific), diluted 1:20 in sterile water with chloramphenicol (50 mg/ml; Sigma), vortexed, and spread on Sabouraud dextrose agar plates. Plates were incubated for 3 d at room temperature and colonies were counted. Each condition was incubated in
duplicate and subsequently plated in duplicate. For each experiment, two sets of cell wells containing C. neoformans, medium, and PHS, but no effector cells, were included. One set was incubated at 4° C, thereby inhibiting CN growth and representing the inoculum size; the second set was incubated at 37° C to determine unrestricted fungal growth. Both were
processed and plated, and colony-forming units determined, as described
for the cell cultures. The results of each experiment are expressed as percent growth according to the following formula: [(CFUexperimental group/
CFU4° C)
1] × 100. Thus, a value of 0 indicates that the number of colony-forming units at the conclusion of incubation was the same as that at the start and that no net fungal growth occurred. Positive values denote
fungal growth, with values of 100 and 300% indicating averages of one
and two replications per fungal cell, respectively. Negative values mean a
decrement in colony-forming units occurred during the course of incubation; therefore, fungal killing took place. It must be recognized, however,
that during the incubation of fungi with effector cells, some fungi may be
killed while others replicate. Therefore, fungal killing could still take place
even if a positive value for percent growth is obtained.
Binding and Internalization Assays
BALCs (5 × 105) were placed in each well of a two-well Lab-Tek chamber slide (Nunc, Naperville, IL) in serum-free culture medium for 24 h and
then infected in vitro with HIV-1 or left uninfected as described earlier.
Chamber slides were then incubated for 14 d (37° C, 5% CO2) with periodic aspiration of supernatants as described. Rhodamine B isothiocyanate
(RITC; Sigma)-labeled heat-inactivated CN prepared as described (15)
was then added to each well at a macrophage:yeast ratio of 1:10 in 1.0 ml
of medium with PHS. Cultures were incubated for 30 min for the binding
assay or for 1 h for the internalization assay. After incubation, AM
were washed three times in PBS to remove unbound fungi. The AM
were then fixed, permeabilized, and stained with fluorescent phalloidin (Molecular Probes, Eugene, OR) for 30 min. Confocal laser scanning microscopy
(Leica, Deerfield, IL) was utilized to count bound and internalized yeast.
Binding was measured by counting the number of yeast adhering to 200 macrophages, excluding internalized yeast. Adherent yeast are discriminated from internalized yeast by examining incremental 1-µm optical sections through each macrophage. The binding index was calculated as the
number of bound yeast divided by the total number of macrophages
counted. To measure internalization, 100 macrophages and any associated
intracellular yeast were counted by examining incremental 1-µm optical
sections through each macrophage by confocal microscopy. The internalization index was calculated as the number of internalized yeast divided
by the total number of macrophages counted.
Macrophage Viability Assay
The viability of HIV-1-infected and uninfected AM
was measured on
Day 14 by colorimetric Alamar Blue assay. Alamar Blue dye undergoes a colorimetric change from blue to red when exposed to viable
cells (17). Uninfected and HIV-infected cell cultures were exposed for
4 h to Alamar Blue dye. Absorbance at wavelength 570 and 600 nm
was determined with an optical density colorimeter plate reader (Molecular Devices, Menlo Park, CA). Specific absorbance was determined by subtracting the latter value from the former.
Statistical Analysis
Results of experiments comparing uninfected and HIV-1-infected
AM
were analyzed by paired, Wilcoxon signed rank test, using Graphpad (San Diego, CA) Instat statistical software.
| |
RESULTS |
|---|
|
|
|---|
Infection of Human Alveolar Macrophages with HIV-1Bal In Vitro
To investigate the effect of HIV-1 on the fungistatic capacity
of human macrophages, AM
were infected with HIV-1Bal as
described in METHODS. The extent of virus replication in these
cultures was determined by measurement of p24 antigen in
culture supernatant on Day 14. The level of p24 antigen in supernatant of Day 14-infected AM
ranged from 1.0 × 104 to
9.4 × 104 pg/ml (mean ± SD, 4.4 × 104 ± 1.6 × 104 pg/ml). No
p24 antigen was detected in any of the uninfected AM
cultures. The proportion of HIV-1-infected AM
from six donors was determined by flow cytometry after permeabilization and
staining for intracellular p24 (Figure 1). At 14 d postinfection,
the majority of AM
were p24 antigen positive (mean percent
p24-positive cells ± SD, 79 ± 15%).
|
Effect of HIV-1 Infection on Alveolar Macrophage Fungistatic Activity
To measure fungistatic activity, control AM
cultures and
HIV-1-infected AM
cultures were challenged with CN on
Day 14 postinfection. Each experiment used AM
from a single donor. The AM
from 7 of 10 donors exhibited fungicidal
activity against CN as demonstrated by a reduction in colony-forming units below the infecting dose (negative percent CN
growth; Figure 2). Infection with HIV-1 reduced fungicidal or
fungistatic activity mediated by AM
from all 10 donors, causing a switch from negative percent CN growth to positive percent CN growth in six cases. By combining all experiments, there was a significant decrease of fungistatic activity in the HIV-1-infected AM
when compared with the uninfected
AM
(mean percent fungistatic growth ± SD,
9 ± 70% for
uninfected cells versus 79 ± 75% for HIV-1 infected cells; p = 0.0020). There was no evident correlation between the peak
p24 antigen level and the measured impairment in fungistatic
activity (data not shown).
|
A time-course experiment was conducted to determine the
kinetics of impaired fungistatic activity in HIV-1-infected
AM
cultures. Antifungal assays were performed on HIV-1-infected and uninfected AM
from a single donor on Days 4, 7, 11, and 13 after HIV-1 infection (Figure 3). On Day 4 there
was no difference in percent CN growth in comparing control
and HIV-1-infected AM
, with both cultures demonstrating
fungicidal activity. Although maximal impairment of antifungal activity was not observed in the HIV-1-infected AM
until
Day 13, there was a degree of impairment noted by Day 7, at
which time 34% of the AM
exhibited intracytoplasmic p24 by flow cytometry. The development of reduced fungistatic
activity correlated with the spread of virus through the culture, but it cannot be determined from these data whether the
effect of HIV-1 on AM
function is a direct consequence of
infection or if it is caused by a soluble factor released from infected cells that also acts on the uninfected AM
population.
While the HIV-1-infected AM
had reduced anticryptococcal
activity compared with control AM
, CN growth was still restricted by the HIV-1-infected cells as compared with CN
growth in medium alone (data not shown).
|
The antifungal assay measures the performance of the entire cell culture on the basis of the number of macrophages initially plated. By light microscopy there were no gross cytopathic effects or cell dropout in the HIV-1-infected AM
cultures. Nonetheless, the observed loss of macrophage fungicidal activity could have resulted from cytotoxicity rather than
a specific functional derangement induced by virus infection.
We therefore examined the viability of uninfected AM
and
HIV-1-infected AM
by means of the Alamar Blue assay. No
significant difference in AM
viability was observed on comparing uninfected and HIV-1-infected cells (mean optical density [OD] ± SD, 0.23 ± 0.13 for uninfected cells versus 0.24 ± 0.01 for HIV-1-infected cells; p = 0.63). Qualitatively similar results were obtained by trypan blue dye staining (data not
shown). Therefore, the effect of HIV-1 to inhibit AM
fungicidal activity is not a consequence of reduced macrophage viability.
Effect of HIV-1 Infection on Alveolar Macrophage Binding and Internalization of Cryptococcus neoformans
Our experiments demonstrate that HIV-1 impairs fungicidal
activity without reducing AM
viability. This functional derangement could be caused by reduced binding or internalization of yeast. Alternatively, reduced fungicidal activity with intact phagocytosis would suggest a defect of intracellular
antimicrobial processing. To examine the first possibility, we
challenged control AM
and HIV-1-infected AM
with CN
that was labeled with rhodamine B isothiocyanate. Macrophages were incubated with labeled CN for 30 min to measure binding, and for 60 min to measure internalization. After
counterstaining with phalloidin, slides were analyzed by confocal microscopy. By examining optical sections through cells,
this method permits clear discrimination between extracellular cell-associated CN versus intracellular CN. No significant
difference in either binding or internalization was found between HIV-1-infected AM
and uninfected AM
(Table 1).
|
| |
DISCUSSION |
|---|
|
|
|---|
We investigated whether in vitro HIV-1 infection could influence the capacity of human AM
to bind, internalize, and kill CN yeast. Our data demonstrate that HIV-1 infection of AM
impairs the normal ability of these cells to kill CN. This effect
does not result from virus-mediated cytotoxicity, or from altered ability of AM
to bind or internalize yeast.
Cameron and coworkers (18) reported that in vitro HIV-1
infection inhibits the antifungal activity of human monocyte-derived macrophages and peritoneal macrophages, but not
that of AM
. Preservation of AM
function in that study may
have been due to lower rates of viral replication in AM
than
in other macrophage types. The antifungal assay measures the
combined performance of all AM
in culture. To observe a
change in this parameter, a large proportion of the AM
must
be affected. Both studies employed the same M-tropic HIV-1
isolate, but the spread of infection and the level of viral replication may have differed significantly. A high proportion of
AM
were infected in the current study, whereas Cameron
and coworkers did not directly measure the proportion of infected cells.
Another variable that may have compromised detection of significant differences in the HIV-1 infected AM
in the study by Cameron and coworkers concerns the level of complement in human serum; complement is an important CN opsonin necessary
for the fungicidal activity of AM
(10). The level of complement
activity in the serum used in our study, compared with that used
by Cameron and coworkers, may have contributed to the differing
results. Finally, we used a virulent cryptococcal strain, whereas
Cameron and coworkers used a hypovirulent strain that was deficient in its ability to make capsule under physiologic conditions.
The reduction in fungistatic activity that we observed does
not manifest until at least 1 wk after HIV-1 infection. The influence of HIV-1 infection on AM
function correlates with
the fraction of infected cells as measured by intracellular p24
staining but is not the result of a cytolytic effect of the virus.
While the impairment of antifungal activity was maximal 14 d
after virus infection, there was evidence of HIV-1 infection as
early as 4 d postinoculation. The delayed kinetics of this
pathological effect of HIV-1 may be due to the time required
for a critical proportion of AM
to become infected. However, our data do not exclude a mechanism involving some cumulative effect of virus infection on intracellular processes.
Binding and phagocytosis of CN is a prerequisite step in the
fungicidal activity of AM
. Reduced phagocytic activity of macrophages for Pneumocystis carinii and Staphylococcus aureus after in vitro HIV-1 infection, or of macrophages of HIV-1-infected
donors with and without pneumonia, has been reported by others
(19, 20). Denis and Ghadirian reported that phagocytic activity for
Mycobacterium avium of AM
from HIV-1-seropositive donors
was no different from that of control subjects (21). We previously
reported that treatment of AM
with HIV-1 envelope protein
gp120 inhibited antifungal activity and reduced phagocytosis, but
not surface binding of CN (11). To evaluate this function we used
confocal microscopy to examine optical sections through HIV-1-infected AM
and uninfected control AM
incubated with
RITC-conjugated CN. We found no difference between these
conditions for either binding or internalization of yeast, indicating
that productive HIV-1 infection affects macrophage antifungal activity at a postphagocytic step.
The effects of HIV-1 infection on CD4+ T cell survival and
adaptive immunity are well recognized. Our data presented
here suggest that a parallel mechanism to incapacitate innate
immune function may also be operating in the lung. Our data
also support an intracellular viral effect, although what the
mechanism of impairment is remains unclear. Important AM
responses involved in the handling of CN include phagosome-
lysosome fusion, generation of reactive oxygen and nitrogen
intermediates, and production of cytokines (22). Investigation of these functions in AM
infected with HIV-1 in vitro
may reveal the mechanism(s) of reduced antifungal activity and identify potential sites for therapeutic interventions in AIDS-related lung disease.
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Hardy Kornfeld, M.D., Pulmonary Center, R-3, Boston University School of Medicine, 80 East Concord Street, Boston, MA 02118. E-mail: hkornfeld{at}lung.bumc.bu.edu
(Received in original form December 13, 1999 and in revised form March 17, 2000).
Acknowledgments: The authors thank Dr. Jussi Saukkonen for technical advice on flow cytometry and Drs. Saukkonen and Joseph Keane for assistance with bronchoscopy.
Supported by Grant RO1 AI25780 from the National Institute of Allergy and Infectious Diseases, and by Grant RO1 HL44846 from the National Heart, Lung, and Blood Institute. Michael Ieong is the recipient of an American Lung Association Research Training Fellowship Award. Christine Campbell Reardon is the recipient of a Parker B. Francis Fellowship Award.
| |
References |
|---|
|
|
|---|
1. Trentin, L., S. Garbisa, R. Zambello, C. Agostini, D. Caenazzo, C. Francesco, A. Cipriani, E. Francavilla, and G. Semenzato. 1992. Spontaneous production of interleukin-6 by alveolar macrophages from human immunodeficiency virus type 1-infected patients. J. Infect. Dis. 166: 731-737 [Medline].
2. Millar, A. B., R. F. Miller, N. M. Foley, A. Meager, S. J. Semple, and G. A. Rook. 1991. Production of tumor necrosis factor-alpha by blood and lung mononuclear phagocytes from patients with human immunodeficiency virus-related lung disease. Am. J. Respir. Cell Mol. Biol. 5: 144-148 .
3. Koziel, H., and J. E. Shellito. 1997. Macrophage function in Pneumocystis carinii infection. In M. F. Lipscomb and S. W. Russell, editors. Lung Macrophages and Dendritic Cells in Health and Disease. Marcel Dekker, New York. 481-520.
4. Lebargy, F., A. Branellec, L. Deforges, J. Bignon, and J. F. Bernaudin. 1994. HIV-1 in human alveolar macrophages from infected patients is latent in vivo but replicates after in vitro stimulation. Am. J. Respir. Cell Mol. Biol. 10: 72-78 [Abstract].
5.
Koziel, H.,
S. Kim,
C. Reardon,
X. Li,
P. Pinkston, and
H. Kornfeld.
1999.
Enhanced in vivo HIV-1 replication in the lungs of HIV-infected persons with Pneumocystis carinii pneumonia.
Am. J. Respir.
Crit. Care Med.
160:
2048-2055
6. Nakata, K., W. N. Rom, Y. Honda, R. Condos, S. Kanegasaki, Y. Cao, and M. Weiden. 1997. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am. J. Respir. Crit. Care Med. 155: 996-1003 [Abstract].
7. Bush, C. E., R. M. Donovan, N. P. Markowitz, P. Kvale, and L. D. Saravolatz. 1996. A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. J. AIDS 13: 23-26 .
8. Lu, W., and D. Israel-Biet. 1993. Virion concentration in bronchoalveolar lavage fluids of HIV infected patients. Lancet 342: 298 [Medline].
9. Minamoto, G. Y., and A. S. Rosenberg. 1997. Fungal infections in patients with acquired immunodeficiency syndrome. Med. Clin. N. Am. 81: 381-409 [Medline].
10. Weinberg, P. B., S. Becker, D. L. Granger, and H. S. Koren. 1987. Growth inhibition of Cryptococcus neoformans by human alveolar macrophages. Am. Rev. Respir. Dis. 136: 1242-1247 [Medline].
11. Wagner, R. P., S. M. Levitz, A. Tabuni, and H. Kornfeld. 1992. HIV-1 envelope protein (gp120) inhibits the activity of human bronchoalveolar macrophages against Cryptococcus neoformans. Am. Rev. Respir. Dis. 146: 1434-1438 [Medline].
12. BAL Cooperative Group Steering Committee. 1990. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am. Rev. Respir. Dis. 141: S169-S202 [Medline].
13. Knapp, W., O. Majdic, and H. Strobl. 1993. Flow cytometric analysis of intracellular myeloperoxidase and lactoferrin in leukemia diagnosis. Rec. Res. Can. Res. 131: 31-40 .
14. Chassagne, J., P. Verrelle, C. Dionet, F. Clavel, F. Barré-Sinoussi, J. C. Chermann, L. Montagnier, J. C. Gluckman, and D. Klatzmann. 1986. A monoclonal antibody against LAV Gag precursor: use for viral protein analysis and antigenic expression in infected cells. J. Immunol. 136: 1442-1445 [Abstract].
15. Levitz, S. M., E. A. North, M. P. Dupont, and T. S. Harrison. 1995. Mechanisms of inhibition of Cryptococcus neoformans by human lymphocytes. Infect. Immun. 63: 3550-3554 [Abstract].
16.
Levitz, S. M., and
T. P. Farrell.
1990.
Growth inhibition of Cryptococcus
neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface, and cytokines.
Infect. Immun.
58:
1201-1209
17. Zhi-Jun, Y., N. Sriranganathan, T. Vaught, S. K. Arastu, and S. A. Ahmed. 1997. A dye-based lymphocyte proliferation assay that permits multiple immunological analyses: mRNA, cytogenetic, apoptosis, and immunophenotyping studies. J. Immunol. Methods. 210: 25-39 [Medline].
18. Cameron, M. L., D. L. Granger, T. J. Matthews, and J. B. Weinberg. 1994. Human immunodeficiency virus (HIV)-infected human blood monocytes and peritoneal macrophages have reduced anticryptococcal activity whereas HIV-infected alveolar macrophages retain normal activity. J. Infect. Dis. 170: 60-67 [Medline].
19. Koziel, H., Q. Eichbaum, B. A. Kruskal, P. Pinkston, R. A. Rogers, M. Y. Armstrong, F. F. Richards, R. M. Rose, and R. A. Ezekowitz. 1998. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J. Clin. Invest. 102: 1332-1344 [Medline].
20. Musher, D. M., D. A. Watson, D. Nickeson, F. Gyorkey, C. Lahart, and R. D. Rossen. 1990. The effect of HIV infection on phagocytosis and killing of Staphylococcus aureus by human pulmonary alveolar macrophages. Am. J. Med. Sci. 299: 158-163 [Medline].
21. Denis, M., and E. Ghadirian. 1994. Interaction between Mycobacterium avium and human immunodeficiency virus type 1 (HIV-1) in bronchoalveolar macrophages of normal and HIV-1-infected subjects. Am. J. Respir. Cell Mol. Biol. 11: 487-495 [Abstract].
22. Harrison, T. S., and S. M. Levitz. 1997. Interactions between lung macrophages and fungi. In M. F. Lipscomb and S. W. Russell, editors. Lung Macrophages and Dendritic Cells in Health and Disease. Marcel Dekker, New York. 521-549.
23. Harrison, T. S., and S. M. Levitz. 1997. Mechanisms of impaired anticryptococcal activity of monocytes from donors infected with human immunodeficiency virus. J. Infect. Dis. 176: 537-540 [Medline].
24. Coffey, M. J., S. M. Phare, P. H. Kazanjian, and M. Peters-Golden. 1996. 5-Lipoxygenase metabolism in alveolar macrophages from subjects infected with the human immunodeficiency virus. J. Immunol. 157: 393-399 [Abstract].
25. Coffey, M. J., S. M. Phare, S. George, M. Peters-Golden, and P. H. Kazanjian. 1998. Granulocyte colony-stimulating factor administration to HIV-infected subjects augments reduced leukotriene synthesis and anticryptococcal activity in neutrophils. J. Clin. Invest. 102: 663-670 [Medline].
This article has been cited by other articles:
![]() |
M. W. Hull, P. Phillips, and J. S. G. Montaner Changing Global Epidemiology of Pulmonary Manifestations of HIV/AIDS Chest, December 1, 2008; 134(6): 1287 - 1298. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pugliese, V. Vidotto, T. Beltramo, and D. Torre Phagocytic Activity in Human Immunodeficiency Virus Type 1 Infection Clin. Vaccine Immunol., August 1, 2005; 12(8): 889 - 895. [Full Text] [PDF] |
||||
![]() |
R. B. Day, Y. Wang, K. S. Knox, R. Pasula, W. J. Martin II, and H. L. Twigg III Alveolar Macrophages from HIV-Infected Subjects are Resistant to Mycobacterium tuberculosis In Vitro Am. J. Respir. Cell Mol. Biol., March 1, 2004; 30(3): 403 - 410. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.J. CANT, S.B. GORDON, R.C. READ, C.A. HART, and C. WINSTANLEY Respiratory infections: Proceedings of the Eighth Liverpool Tropical School Bayer Symposium of Microbial Disease held on 3 February 2001 J. Med. Microbiol., November 1, 2002; 51(11): 903 - 914. [Full Text] [PDF] |
||||
![]() |
S B Gordon and R C Read Macrophage defences against respiratory tract infections: The immunology of childhood respiratory infections Br. Med. Bull., March 1, 2002; 61(1): 45 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. TOBIN Tuberculosis, Lung Infections, and Interstitial Lung Disease in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1774 - 1788. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Cell Mol. Biol. |